Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 403

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1C
Chunk 403
---
 operations of the Company.

Results
of Operations

Year
Ended December 31, 2024 compared to Year Ended December 31, 2023

The
following tables set forth our results of operations for the years ended December 31, 2024 and 2023 and the relative dollar and percentage
change between the two years.

    Year ended December 31,  
    Change (2024 to 2023) 

    2024  
    2023  
    ($)  
    % 
  
    Operating expenses: 

    Research and development 
    $7,251,097  
    $7,621,707  
    $(370,610) 
     (4.9)%
  
    General and administrative 
     8,114,654  
     8,756,767  
     (642,113) 
     (7.3)%
  
    Total operating expenses 
     15,365,751  
     16,378,474  
     (1,012,723) 
     (6.2)%
  
    Loss from operations 
     (15,365,751) 
     (16,378,474) 
     1,012,723  
     (6.2)%
  
    Other income, net 
     343,724  
     955,003  
     (611,279) 
     (64.0)%
  
    Net loss 
    $(15,022,027) 
    $(15,423,471) 
    $401,444  
     (2.6)%
  
    Net loss attributable to common stockholders per share, basic and diluted 
    $(1.61) 
    $(1.83) 
    $0.22  
     (12.0)%
  
    Weighted average number of shares used in calculating net loss per share, basic and diluted 
     9,355,710  
     8,401,047  

65

Research
and Development Expenses

Our
research and development expenses for the year ended December 31, 2024 amounted to approximately $7.2 million, a decrease of approximately
$0.4 million, or approximately 4.9%, compared with approximately $7.6 million for the year ended December 31, 2023. This decrease